MYC and colorectal carcinoma: In the CMS system, CRC can be classified as CMS1 (immune subtype, with microsatellite instability and strong immune activation), CMS2 (canonical subtype, characterized by epithelial and WNT, MYC and EGFR signaling activation), CMS3 (metabolic subtype, epithelial with metabolic dysregulation), or CMS4 (mesenchymal subtype, with activation of TGFB1, stromal invasion and angiogenesis).